{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:52:23Z","timestamp":1791571943219,"version":"4.3.4"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:p>Survival rates of human immunodeficiency virus-positive subjects improved in recent years, especially due to innovations in current lymphoma treatments and the addition of combination antiretroviral therapy (cART). This study presents demographic and clinical characteristics, prognosis, and survival data of acquired immune deficiency syndrome (AIDS)-related lymphoma patients as a single-center experience. This retrospective study included 16 patients with AIDS-related lymphoma treated at our center between August 2010 and March 2022. Demographic data, clinical information, treatment details, and survival analysis of the patients were retrospectively reviewed from the relevant clinical archives. Fifteen out of 16 patients were males with a median age of 46.5 years (range, 24\u201371 years). The diagnoses were as follows: diffuse large B-cell lymphoma in 6, Burkitt lymphoma in 4, Hodgkin lymphoma in 3, plasmablastic lymphoma in 1, primary central nervous system lymphoma in 1, and chronic lymphocytic leukemia in 1 out of 16 patients. Fifteen patients presented with an advanced stage at diagnosis. Diagnosis of AIDS preceded the onset of lymphoma in 11 patients. The time from human immunodeficiency virus infection to diagnosis of lymphoma was 23.8 months (range, 1\u2013185 months). All patients received cART during lymphoma treatment. The treatment response was evaluated in all patients who completed the initial treatment. Eleven patients (68.8%) are still alive with a complete response. Antitumour treatments administered in conjunction with cART have a favorable impact on survival and response rates in this aggressive group of patients.<\/jats:p>","DOI":"10.1097\/md.0000000000047992","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:01:24Z","timestamp":1773043284000},"page":"e47992","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["HIV-associated lymphoproliferative disorders: Single-center experience"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-8759","authenticated-orcid":false,"given":"Derya","family":"Demirtas","sequence":"first","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayfur","family":"Toptas","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asu Fergun","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"Erturk Sengel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Marmara, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Yuksel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Marmara, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Emre","family":"Kokkaya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Marmara, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Candan","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Mert","family":"Yanik","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secil","family":"Salim","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Ulukoylu Menguc","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Arikan","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isik","family":"Atagunduz","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Korten","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Marmara, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Tulin","family":"Tuglular","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Marmara, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","article-title":"Epidemiology of haematological malignancies in people living with HIV.","volume":"7","author":"Kimani","year":"2020","journal-title":"Lancet HIV"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I treat HIV-associated lymphoma.","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/10428194.2015.1055483","article-title":"HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population.","volume":"57","author":"Riedel","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/QAD.0b013e3282f2705d","article-title":"Non-Hodgkin lymphoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy.","volume":"22","author":"Polesel","year":"2008","journal-title":"AIDS"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal trends in presentation and survival for HIVassociated lymphoma in the antiretroviral therapy era.","volume":"105","author":"Gopal","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1093\/cid\/ciaa1016","article-title":"Deaths attributable to cancer in the US human immunodeficiency virus population during 2001\u20132015.","volume":"72","author":"Horner","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ejh.13082","article-title":"Malignant lymphoma in the HIV-positive patient.","volume":"101","author":"Meister","year":"2018","journal-title":"Eur J Haematol"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"919446","DOI":"10.3389\/fcimb.2022.919446","article-title":"A novel prognostic score including the CD4\/CD8 for AIDS-related lymphoma.","volume":"12","author":"Chen","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"O2","DOI":"10.1186\/1750-9378-4-S2-O2","article-title":"Incidence and risk factors of HIV-associated non-Hodgkin-lymophma in the era combined anti-retroviral therapy. a European multi-cohort study.","volume":"4","author":"Bohlius","year":"2009","journal-title":"Infect Agent Cancer"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/PPO.0000000000000448","article-title":"HIV lymphoma and burkitts lymphoma.","volume":"26","author":"Noy","year":"2020","journal-title":"Cancer J"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"7588928","DOI":"10.1155\/2024\/7588928","article-title":"The trends and risk factors of AIDS-defining cancers and non-AIDS-defining cancers in adults living with and without HIV: a narrative review.","volume":"2024","author":"Mathoma","year":"2024","journal-title":"J Cancer Epidemiol"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QAD.0b013e3282f47082","article-title":"Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals.","volume":"22","author":"Long","year":"2008","journal-title":"AIDS"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:08:51Z","timestamp":1791569331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047992","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2025-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}